Frequency and Type of Epidermal Growth Factor Receptor Mutations in Moroccan Patients with Lung Adenocarcinoma

被引:23
作者
Errihani, Hassan [1 ]
Inrhaoun, Hanane [1 ]
Boukir, Anouar [1 ]
Kettani, Fouad [2 ]
Gamra, Lamia [3 ]
Mestari, Amina [4 ]
Jabri, Lamia [5 ]
Bensouda, Youssef [1 ]
Mrabti, Hind [1 ]
Elghissassi, Ibrahim [1 ]
机构
[1] Natl Inst Oncol, Dept Med Oncol, Rabat 62000, Morocco
[2] Nations Unies Pathol Ctr, Dept Pathol, Rabat, Morocco
[3] Hassan Pathol Ctr, Dept Pathol, Rabat, Morocco
[4] Agdal Pathol Ctr, Dept Pathol, Rabat, Morocco
[5] Casapath Pathol Ctr, Dept Pathol, Casablanca, Morocco
关键词
Epidermal growth factor receptor mutation; Morocco; Frequency; EGFR MUTATION; GEFITINIB; CANCER; POPULATION;
D O I
10.1097/JTO.0b013e31829f6b4a
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer predict response to tyrosine kinase inhibitors. The frequency of EGFR mutations is ethnicity-dependent, with a higher proportion in Asian populations than in whites. The prevalence of these mutations among North African patients is unknown. The objective of this study was to report the frequency and spectrum of EGFR mutations in a group of Moroccan patients with lung adenocarcinoma (AC). Methods: Tumor specimens from 137 Moroccan patients with lung AC were selected to determine frequency and spectrum of EGFR mutations. Mutation detection techniques were polymerase chain reaction amplification and sequencing of exons 18, 19, 20, and 21. Results: The overall frequency of the EGFR mutation was 21%. Mutations were mainly detected in the exon 19 (69%), followed by exon 21 (21%) and exon 20 (7%), whereas mutations in the exon 18 were rare (3%). EGFR mutation rate was significantly higher in women and in never smokers. Conclusion: Some one fifth of lung AC tumors in Moroccan patients harbor EGFR mutations. This mutation frequency is higher than that found in whites but lower than in Asian population. Further studies, in larger numbers of patients, are needed to confirm these findings.
引用
收藏
页码:1212 / 1214
页数:3
相关论文
共 14 条
  • [1] Epidermal Growth Factor Recetor mutation study for 5 years, in a population of patients with non-small cell lung cancer
    Castro, A. S.
    Parente, B.
    Goncalves, I.
    Antunes, A.
    Barroso, A.
    Conde, S.
    Neves, S.
    Machado, J. C.
    [J]. REVISTA PORTUGUESA DE PNEUMOLOGIA, 2013, 19 (01) : 7 - 12
  • [2] EGFR Mutation Testing in Patients with Advanced Non-Small Cell Lung Cancer: A Comprehensive Evaluation of Real-World Practice in an East Asian Tertiary Hospital
    Choi, Yoon-La
    Sun, Jong-Mu
    Cho, Juhee
    Rampal, Sanjay
    Han, Joungho
    Parasuraman, Bhash
    Guallar, Eliseo
    Lee, Genehee
    Lee, Jeeyun
    Shim, Young Mog
    [J]. PLOS ONE, 2013, 8 (02):
  • [3] The role of EGFR inhibitors in nonsmall cell lung cancer
    Ciardiello, F
    De Vita, F
    Orditura, M
    Tortora, G
    [J]. CURRENT OPINION IN ONCOLOGY, 2004, 16 (02) : 130 - 135
  • [4] EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study
    de Mello, Ramon Andrade
    Pires, Filipa Soares
    Marques, Dania Sofia
    Oliveira, Julio
    Rodrigues, Ana
    Soares, Marta
    Azevedo, Isabel
    Peixoto, Ana
    Santos, Catarina
    Pinto, Carla
    Hespanhol, Venceslau
    Teixeira, Manuel R.
    Amaro, Teresina
    Queiroga, Henrique
    Araujo, Antonio
    [J]. TUMOR BIOLOGY, 2012, 33 (06) : 2061 - 2068
  • [5] High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan
    Huang, SF
    Liu, HP
    Li, LH
    Ku, YC
    Fu, YN
    Tsai, HY
    Chen, YT
    Lin, YF
    Chang, WC
    Kuo, HP
    Wu, YC
    Chen, YR
    Tsai, SF
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (24) : 8195 - 8203
  • [6] Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib
    Jackman, David M.
    Yeap, Beow Y.
    Sequist, Lecia V.
    Lindeman, Neal
    Holmes, Alison J.
    Joshi, Victoria A.
    Bell, Daphne W.
    Huberman, Mark S.
    Halmos, Balazs
    Rabin, Michael S.
    Haber, Daniel A.
    Lynch, Thomas J.
    Meyerson, Matthew
    Johnson, Bruce E.
    Jaenne, Pasi A.
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (13) : 3908 - 3914
  • [7] Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI [10.3322/caac.20006, 10.3322/caac.21387]
  • [8] Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
    Mok, Tony S.
    Wu, Yi-Long
    Thongprasert, Sumitra
    Yang, Chih-Hsin
    Chu, Da-Tong
    Saijo, Nagahiro
    Sunpaweravong, Patrapim
    Han, Baohui
    Margono, Benjamin
    Ichinose, Yukito
    Nishiwaki, Yutaka
    Ohe, Yuichiro
    Yang, Jin-Ji
    Chewaskulyong, Busyamas
    Jiang, Haiyi
    Duffield, Emma L.
    Watkins, Claire L.
    Armour, Alison A.
    Fukuoka, Masahiro
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) : 947 - 957
  • [9] Rahman S, 2013, INT J CLIN ONCOL
  • [10] Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer.
    Rosell, Rafael
    Moran, Teresa
    Queralt, Cristina
    Porta, Rut
    Cardenal, Felipe
    Camps, Carlos
    Majem, Margarita
    Lopez-Vivanco, Guillermo
    Isla, Dolores
    Provencio, Mariano
    Insa, Amelia
    Massuti, Bartomeu
    Luis Gonzalez-Larriba, Jose
    Paz-Ares, Luis
    Bover, Isabel
    Garcia-Campelo, Rosario
    Angel Moreno, Miguel
    Catot, Silvia
    Rolfo, Christian
    Reguart, Noemi
    Palmero, Ramon
    Miguel Sanchez, Jose
    Bastus, Roman
    Mayo, Clara
    Bertran-Alamillo, Jordi
    Angel Molina, Miguel
    Javier Sanchez, Jose
    Taron, Miquel
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) : 958 - U38